000168394 001__ 168394
000168394 005__ 20240229133607.0
000168394 0247_ $$2doi$$a10.1186/s12916-021-01952-3
000168394 0247_ $$2pmid$$apmid:33781249
000168394 0247_ $$2pmc$$apmc:PMC8008592
000168394 0247_ $$2altmetric$$aaltmetric:102980962
000168394 037__ $$aDKFZ-2021-00881
000168394 041__ $$aEnglish
000168394 082__ $$a610
000168394 1001_ $$aMatta, Michèle$$b0
000168394 245__ $$aDietary intake of trans fatty acids and breast cancer risk in 9 European countries.
000168394 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2021
000168394 3367_ $$2DRIVER$$aarticle
000168394 3367_ $$2DataCite$$aOutput Types/Journal article
000168394 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1618987138_3170
000168394 3367_ $$2BibTeX$$aARTICLE
000168394 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168394 3367_ $$00$$2EndNote$$aJournal Article
000168394 520__ $$aTrans fatty acids (TFAs) have been hypothesised to influence breast cancer risk. However, relatively few prospective studies have examined this relationship, and well-powered analyses according to hormone receptor-defined molecular subtypes, menopausal status, and body size have rarely been conducted.In the European Prospective Investigation into Cancer and Nutrition (EPIC), we investigated the associations between dietary intakes of TFAs (industrial trans fatty acids [ITFAs] and ruminant trans fatty acids [RTFAs]) and breast cancer risk among 318,607 women. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models, adjusted for other breast cancer risk factors.After a median follow-up of 8.1 years, 13,241 breast cancer cases occurred. In the multivariable-adjusted model, higher total ITFA intake was associated with elevated breast cancer risk (HR for highest vs lowest quintile, 1.14, 95% CI 1.06-1.23; P trend = 0.001). A similar positive association was found between intake of elaidic acid, the predominant ITFA, and breast cancer risk (HR for highest vs lowest quintile, 1.14, 95% CI 1.06-1.23; P trend = 0.001). Intake of total RTFAs was also associated with higher breast cancer risk (HR for highest vs lowest quintile, 1.09, 95% CI 1.01-1.17; P trend = 0.015). For individual RTFAs, we found positive associations with breast cancer risk for dietary intakes of two strongly correlated fatty acids (Spearman correlation r = 0.77), conjugated linoleic acid (HR for highest vs lowest quintile, 1.11, 95% CI 1.03-1.20; P trend = 0.001) and palmitelaidic acid (HR for highest vs lowest quintile, 1.08, 95% CI 1.01-1.16; P trend = 0.028). Similar associations were found for total ITFAs and RTFAs with breast cancer risk according to menopausal status, body mass index, and breast cancer subtypes.These results support the hypothesis that higher dietary intakes of ITFAs, in particular elaidic acid, are associated with elevated breast cancer risk. Due to the high correlation between conjugated linoleic acid and palmitelaidic acid, we were unable to disentangle the positive associations found for these fatty acids with breast cancer risk. Further mechanistic studies are needed to identify biological pathways that may underlie these associations.
000168394 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000168394 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168394 650_7 $$2Other$$aBreast cancer
000168394 650_7 $$2Other$$aDiet
000168394 650_7 $$2Other$$aIndustrial trans fatty acids
000168394 650_7 $$2Other$$aRuminant trans fatty acids
000168394 7001_ $$aHuybrechts, Inge$$b1
000168394 7001_ $$aBiessy, Carine$$b2
000168394 7001_ $$aCasagrande, Corinne$$b3
000168394 7001_ $$aYammine, Sahar$$b4
000168394 7001_ $$aFournier, Agnès$$b5
000168394 7001_ $$aOlsen, Karina Standahl$$b6
000168394 7001_ $$aLukic, Marco$$b7
000168394 7001_ $$aGram, Inger Torhild$$b8
000168394 7001_ $$aArdanaz, Eva$$b9
000168394 7001_ $$aSánchez, Maria-José$$b10
000168394 7001_ $$aDossus, Laure$$b11
000168394 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée T$$b12$$udkfz
000168394 7001_ $$0P:(DE-He78)0644671d309776d45e0fc705d1156cac$$aSrour, Bernard$$b13$$udkfz
000168394 7001_ $$aJannasch, Franziska$$b14
000168394 7001_ $$aSchulze, Matthias B$$b15
000168394 7001_ $$aAmiano, Pilar$$b16
000168394 7001_ $$aAgudo, Antonio$$b17
000168394 7001_ $$aColorado-Yohar, Sandra$$b18
000168394 7001_ $$aQuirós, J Ramón$$b19
000168394 7001_ $$aTumino, Rosario$$b20
000168394 7001_ $$aPanico, Salvatore$$b21
000168394 7001_ $$aMasala, Giovanna$$b22
000168394 7001_ $$aPala, Valeria$$b23
000168394 7001_ $$aSacerdote, Carlotta$$b24
000168394 7001_ $$aTjønneland, Anne$$b25
000168394 7001_ $$aOlsen, Anja$$b26
000168394 7001_ $$aDahm, Christina C$$b27
000168394 7001_ $$aRosendahl, Ann H$$b28
000168394 7001_ $$aBorgquist, Signe$$b29
000168394 7001_ $$aWennberg, Maria$$b30
000168394 7001_ $$aHeath, Alicia K$$b31
000168394 7001_ $$aAune, Dagfinn$$b32
000168394 7001_ $$aSchmidt, Julie$$b33
000168394 7001_ $$aWeiderpass, Elisabete$$b34
000168394 7001_ $$aChajes, Veronique$$b35
000168394 7001_ $$aGunter, Marc J$$b36
000168394 7001_ $$aMurphy, Neil$$b37
000168394 773__ $$0PERI:(DE-600)2131669-7$$a10.1186/s12916-021-01952-3$$gVol. 19, no. 1, p. 81$$n1$$p81$$tBMC medicine$$v19$$x1741-7015$$y2021
000168394 909CO $$ooai:inrepo02.dkfz.de:168394$$pVDB
000168394 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000168394 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0644671d309776d45e0fc705d1156cac$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000168394 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000168394 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000168394 9141_ $$y2021
000168394 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC MED : 2019$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2021-01-29
000168394 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBMC MED : 2019$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-29
000168394 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-29
000168394 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000168394 980__ $$ajournal
000168394 980__ $$aVDB
000168394 980__ $$aI:(DE-He78)C020-20160331
000168394 980__ $$aUNRESTRICTED